Chemoembolization (TACE)
- TACE (transarterial chemoembolization) treats liver tumors by feeding them poison and then cutting off their food supply — chemotherapy plus a clot, delivered straight to the tumor's artery.
- It works because the liver has a double blood supply: most of the liver lives off the portal vein, but liver tumors (especially HCC) are fed almost entirely by the hepatic artery. That difference is the whole game.
- The classic use is intermediate-stage hepatocellular carcinoma — tumor too big or too many for ablation, but no spread outside the liver and reasonable liver function.
- "Post-embolization syndrome" (pain, fever, nausea) is expected afterward, not a complication. The real dangers are liver failure and injuring the wrong vessel.
- A patent main portal vein and decent liver reserve matter; clotting off the artery in a liver that's already barely coping can tip it over the edge.
Imagine a tumor as a houseguest who refuses to leave and orders takeout constantly. You can't easily kick it out, but you can control the front door it gets its deliveries through. TACE is exactly that move: go to the artery feeding the tumor, dump chemotherapy right onto it, then plug the door so the drug stays put and the tumor starves. It's targeted, local, and satisfyingly mechanical — interventional radiology at its most "let's just fix the plumbing."
Why the liver lets us cheat
Here's the anatomical gift that makes this possible. Normal liver tissue gets most of its blood — roughly three-quarters of it — from the portal vein, the big vein draining your gut. The hepatic artery is the minority partner. But liver tumors are needy and greedy: as hepatocellular carcinoma (HCC) grows, it recruits a new arterial blood supply and ends up fed almost entirely by the hepatic artery.
So if you deliver your treatment through the hepatic artery, the tumor gets a face full of it while the surrounding normal liver shrugs and keeps living off its portal vein. That selective targeting is the entire reason TACE exists.
This same arterial-feeding quirk is why HCC "lights up" so brightly in the arterial phase on contrast CT/MRI and then washes out — the tumor is gulping arterial contrast that the rest of the liver hasn't caught up to yet.
Who gets it (and who shouldn't)
The textbook patient is someone with intermediate-stage HCC: the tumor is too large or too multifocal to just burn out with ablation, but it hasn't spread outside the liver, and the liver itself still works reasonably well. TACE is mostly a tumor-control and life-prolonging play here, not usually a cure on its own.
It also shows up for some neuroendocrine liver metastases and select other hypervascular liver tumors.
The dangerous candidate is the one whose liver is already on the ropes. If you embolize the hepatic artery in a liver with poor function — or with a blocked main portal vein removing the "backup" blood supply — you can starve too much liver at once and push the patient into liver failure. Liver reserve and portal vein status get checked before anyone goes near the angio suite.
How the procedure actually goes
It's an angiogram with a payload. The sequence, roughly:
| Step | What's happening |
|---|---|
| Access | A catheter goes in through a wrist or groin artery and is steered up into the hepatic artery. |
| Map | Contrast is injected to map the arterial anatomy and pinpoint the vessel feeding the tumor. |
| Superselect | A tiny microcatheter is threaded as close to the tumor's feeding artery as possible — the more selective, the more normal liver you spare. |
| Deliver | The chemo-carrying agent is injected, then embolic material plugs the artery so it stays parked in the tumor. |
There are two main flavors. Conventional TACE mixes chemotherapy with lipiodol — an oily contrast that the tumor preferentially holds onto (and that conveniently shows up on later CT, so you can literally see where your treatment landed). DEB-TACE uses drug-eluting beads that carry the chemo and release it slowly while also doing the blocking. Both aim for the same one-two punch: high local drug concentration and ischemia.
Afterward: what's normal and what's not
Almost everyone feels rotten for a few days afterward — pain, low-grade fever, nausea, fatigue. This is post-embolization syndrome, and it's the expected response to killing off tumor tissue, not a sign something went wrong. It's the body's version of grumbling about the dead houseguest being carried out.
Post-embolization syndrome is managed, not feared: pain control, anti-nausea meds, hydration. It typically settles over several days. The job is reassurance plus supportive care, while staying alert for the genuine complications hiding behind the same symptoms.
The complications that actually matter are different beasts. Liver decompensation or failure if too much liver was sacrificed. Non-target embolization — the embolic material drifting into the wrong artery and injuring the gallbladder, stomach, duodenum, or pancreas, which is why mapping the anatomy carefully up front is non-negotiable. And the usual procedural risks: liver abscess, bile duct injury, and access-site problems.
Where it sits among its cousins
TACE isn't the only way to treat a tumor through its artery. Its close relative, Y-90 radioembolization, swaps the chemo-plus-clot for tiny radioactive beads that irradiate the tumor from the inside. And the broader idea of plugging an artery to control a problem is the same logic behind arterial embolization for bleeding and trauma.
If you remember one thing: TACE works because the liver's two-faucet blood supply lets us turn off the tumor's faucet while leaving the liver's own faucet running. Poison the guest, lock the door, spare the house.